We are live on ! Find out more

Celldex Therapeutics

CLDX

Market cap $2.95B

37.51 USD

-0.59

1.55%

At close Updated Sep 11, 11:06 AM EDT

1 day

-1.55%

5 days

-3.72%

1 month

-15.38%

3 months

25.2%

6 months

20.11%

Year to date

38.87%

1 year

48.85%

5 years

-30.61%

10 years

-32.6%

About: Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Employees: 198

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.7%

Neutral 61.5%

Negative 30.8%

Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

Celldex to Present at Upcoming Investor Conference

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Zacks Investment Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Celldex Therapeutics remains a "Strong Buy," driven by barzolvolimab's rapid phase 3 enrollment for chronic spontaneous urticaria [CSU] and multiple late-stage catalysts. EMBARQ-CSU 1 and 2 phase 3 trials completed enrollment six months early; pivotal data expected September/October 2026, with potential BLA filing in 2027 if endpoints are met. Company is diversifying with CDX-622, a bispecific TSLP & SCF inhibitor, showing promising safety and mechanism data in phase 1, targeting asthma and other inflammatory disorders.

Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Zacks Investment Research

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules.

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss

Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies.

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss

Celldex to stop skin disease study after trial setback

Celldex Therapeutics said on Tuesday it would discontinue the development of its experimental drug for a skin disease ‌after it failed to meet the main goal and key secondary goals in a mid-stage study, sending its shares down over 7% in extended trading.

Celldex to stop skin disease study after trial setback

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The primary endpoint of the study, the proportion of patients who achieve a four point or greater improvement in WI-NRS (Worst Itch Numeric Rating Scale) from baseline to Week 12, and key secondary endpoints were not met.

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

See News Rankings

Price charts implemented using Lightweight Charts™